Pfizer Gets FDA Panel's Backing in RSV Vaccine Race

A panel of outside advisers to the US health regulator recommended Pfizer Inc's respiratory syncytial virus vaccine, bringing it closer to becoming one of the first approved RSV shots for older adults in the United States.

Related Keywords

United States ,New York ,Bengaluru ,Karnataka ,India ,Caroline Humer Sriraj Kalluvila ,Manas Mishra ,Khushi Mandowara ,Hana Sahly ,Maju Samuel ,Pfizer ,Pfizer Inc ,Moderna Inc ,Drug Administration ,Johnson ,Reuters ,Mariame Sunny ,Michael Erman ,Caroline Humer ,Sriraj Kalluvila ,Vaccine ,Vaccines ,Respiratory Syncytial Virus Infection ,Adult Respiratory Syncytial Virus Rsv Infection ,Dult Respiratory Syncytial Virus Rsv ,Dult Rsv Infection ,Dult Respiratory Syncytial Virus Infection ,Geriatrics ,Elder Care ,Geriatric Medicine ,Older Adults ,Seniors ,Senior Citizens ,Elderly ,Respiratory Tract ,